scholarly journals Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Yiding Li ◽  
Guiling Wu ◽  
Wanli Yang ◽  
Xiaoqian Wang ◽  
Lili Duan ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Pooled Analysis ◽  
Clinicopathological Characteristics ◽  
Cochrane Library ◽  
Cellsearch System ◽  
Poor Overall Survival ◽  
Response To Chemotherapy ◽  
The Cochrane Library

Abstract Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumor in the world, which is still one of the primary causes of tumor-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding effective treatment. Recently, circulating tumor cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined by the CellSearch system in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as the effect values. Results: Totally 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher rate of CTCs compared with the I/II group (OR=1.36, 95% CI: 0.68-2.71, I2=0%). Incidence of CTCs was higher in patients with T3/T4 stage (OR=2.92, 95% CI: 1.31-6.51, I2=0%) and distant metastasis group (OR=5.18, 95% CI: 2.38-11.25, I2=0%) compared to patients with T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR=2.83, 95% CI:1.99-4.03, I2=0%) and relapse-free survival (RFS) (HR=4.71, 95% CI:2.73-8.13, I2=0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR=1.99, 95% CI:1.73-2.29, I2=60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs positivity determined by the CellSearch system are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

scholarly journals Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Yiding Li ◽  
Guiling Wu ◽  
Wanli Yang ◽  
Xiaoqian Wang ◽  
Lili Duan ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Pooled Analysis ◽  
Tumour Cells ◽  
Cochrane Library ◽  
Circulating Tumour Cells ◽  
Cellsearch System ◽  
Poor Overall Survival ◽  
Response To Chemotherapy

Abstract Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumour in the world, which is still the primary cause of tumour-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding active and effective treatment. Recently, circulating tumour cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined using the CellSearch System in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as effect values. Results: In total, 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher incidence of CTCs compared with the I/II group (OR=1.36, 95% CI (0.68,2.71), I2=0%). Incidence of CTCs was higher among patients on T3/T4 stage (OR=2.92, 95% CI (1.31,6.51), I2=0%) and distant metastasis group (OR=5.18, 95% CI (2.38,11.25), I2=0%) compared to patients on T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR =2.83, 95% CI (1.99,4.03), I2=0%) and relapse-free survival (RFS) (HR =4.71, 95% CI (2.73,8.13), I2=0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR =1.99, 95% CI (1.73,2.29), I2=60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs from PB of EC patients determined using the CellSearch System are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

scholarly journals Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Yiding Li ◽  
Guiling Wu ◽  
Wanli Yang ◽  
Xiaoqian Wang ◽  
Lili Duan ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Pooled Analysis ◽  
Tumour Cells ◽  
Cochrane Library ◽  
Circulating Tumour Cells ◽  
Cellsearch System ◽  
Poor Overall Survival ◽  
Response To Chemotherapy

Abstract Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumour in the world, which is still the primary cause of tumour-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding active and effective treatment. Recently, circulating tumour cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined using the CellSearch System in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as effect values. Results: In total, 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher incidence of CTCs compared with the I/II group (OR=1.36, 95% CI (0.68,2.71), I2=0%). Incidence of CTCs was higher among patients on T3/T4 stage (OR=2.92, 95% CI (1.31,6.51), I2=0%) and distant metastasis group (OR=5.18, 95% CI (2.38,11.25), I2=0%) compared to patients on T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR =2.83, 95% CI (1.99,4.03), I2=0%) and relapse-free survival (RFS) (HR =4.71, 95% CI (2.73,8.13), I2=0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR =1.99, 95% CI (1.73,2.29), I2=60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs from PB of EC patients determined using the CellSearch System are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

scholarly journals LncRNA DLX6-AS1 as a potential molecular biomarker in the clinicopathology and prognosis of various cancers: a meta-analysis

2020 ◽  
Vol 40 (8) ◽  
Author(s):  
Shubo Tian ◽  
Jinglei Liu ◽  
Shuai Kong ◽  
Lipan Peng
Keyword(s):  
Survival Data ◽  
Poor Prognosis ◽  
Meta Analysis ◽  
Tumor Stage ◽  
Clinicopathological Characteristics ◽  
Clinicopathological Features ◽  
High Expression ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
The Cochrane Library

Abstract Objective: Recent studies have shown that distal-less homeobox 6 antisense 1 (DLX6-AS1) is aberrantly expressed in various cancers and is associated with poor prognosis. This meta-analysis is designed to investigate the effects of DLX6-AS1 expression on clinicopathological features and survival outcomes. Methods: All eligible studies were searched from Pubmed, Web of Science, Embase, the Cochrane Library, and Wanfang database, up to August 2019. The literature was selected according to the inclusion and exclusion criteria listed in this work, and the quality of each eligible study was assessed. Each patient’s clinicopathological features and survival data were analyzed using Stata12.0 software. Begg’s test and sensitivity analysis were also conducted. Results: A total of 12 articles were included, covering 841 patients. Results showed that high expression of DLX6-AS1 was significantly closely associated with poor overall survival in tumor patients (hazard ratio (HR) = 2.30, confidence interval (95% CI): 1.70–3.09, P<0.01). This meta-analysis also showed that overexpression of DLX6-AS1 was significantly associated with tumor stage (P<0.01), tumor size (P<0.01), lymph node metastasis (P<0.01), and distant metastasis (P<0.01). Begg’s test suggested no publication bias. Conclusion: This meta-analysis revealed that high expression of DLX6-AS1 was related to the advanced clinicopathological characteristics of human digestive system cancers (gastric cancer, esophageal cancer, colon cancer, pancreatic cancer, and hepatocellular carcinoma) and other cancers such as ovarian cancer, osteosarcoma and non-small cell lung cancer, and DLX6-AS1 has important predictive value for poor prognosis. However, more studies are needed to further corroborate these findings.

scholarly journals 1471Metadata on calprotectin, an emerging biomarker of interest in COVID-19

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Raphael Udeh
Keyword(s):  
Meta Analysis ◽  
Prognostic Significance ◽  
Intervention Strategy ◽  
Pooled Analysis ◽  
Severe Form ◽  
Cochrane Library ◽  
Diagnostic Tools ◽  
Quantitative Studies ◽  
Study Heterogeneity ◽  
The Cochrane Library

Abstract Background COVID-19 has been shown to present with a varied clinical course, hence the need for more specific diagnostic tools that could identify severe cases and predict outcomes during COVID-19 infection. Recent evidence has shown an expanded potential role for calprotectin, both as a diagnostic tool and as a stratifying tool in COVID-19 patients in terms of severity. Therefore, this systematic review and meta-analysis aims to evaluate the levels of calprotectin in severe and non-severe COVID-19 and also identify the implication of raised calprotectin levels. Methods Databases searched include MEDLINE, EMBASE, the Cochrane Library, Web of Science, and MedRxiv. Stata was employed in meta-analysis to compare the serum/faecal levels of calprotectin between severe and non-severe COVID-19 infections. Results A pooled analysis of data in the 8 quantitative studies from 613 patients who were RT-PCR positive for COVID-19 (average age = 55 years; 52% males) showed an overall estimate as 1.34 (95%CI: 0.77, 1.91). Stata was further employed to carry out an in-depth investigation of the in-between study heterogeneity. Conclusion In conclusion, calprotectin levels have been demonstrated to be significantly elevated in COVID-19 patients who develop the severe form of the disease, and it also has prognostic significance. Key message This is the first comprehensive metadata on calprotectin in COVID-19. And as a druggable target for tasquinimod, calprotectin potentially remains a key therapeutic intervention strategy in COVID-19 management.

Prognostic significance of C-MYC dysregulation in esophageal squamous cell carcinoma: a meta-analysis

2020 ◽  
Vol 14 (7) ◽  
pp. 599-609
Author(s):  
Xuejiao Shi ◽  
Renhua Zhou ◽  
Leizhen Zheng ◽  
Mawei Jiang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Web Of Science ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
The Cochrane Library

Aim: The clinicopathological and prognostic significance of C-MYC dysregulation (amplification or overexpression) in esophageal squamous cell carcinoma (ESCC) remains controversial. Therefore, we performed this meta-analysis to elucidate this relationship. Materials & methods: Available studies were retrieved from PubMed, Web of Science, EMBASE and the Cochrane Library, and ten studies with a total of 1432 patients were included in this meta-analysis. Results: Pooled results showed that C-MYC dysregulation was significantly associated with poor overall survival (hazard ratio: 1.405 [95% CI: 1.170–1.639]; p < 0.001) and lymph node metastasis (odds ratio: 1.798 [95% CI: 1.125–2.873]; p = 0.014). Subgroup analysis confirmed the results and more prominent predictive effects were observed in the C-MYC amplification group. Conclusion: C-MYC dysregulation is a promising biomarker for ESCC prognosis.

scholarly journals Clinicopathological significance and prognosis of long noncoding RNA SNHG14 expression in human cancers: A Meta-Analysis and bioinformatics analysis

2021 ◽  
Author(s):  
Bin Liu ◽  
Tingting Lu ◽  
Yongfeng Wang ◽  
Yaqiong Chen ◽  
Shixun Ma ◽  
...  
Keyword(s):  
Noncoding Rna ◽  
Cox Regression ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
Cochrane Library ◽  
Poor Overall Survival ◽  
Significant Difference ◽  
Pan Cancer

Abstract Background SNGH14 is a recently found long non-coding RNA (lncRNA) with a strong link to cancer. However, it is uncertain if the expression of SNHG14 is linked to the prognosis of individuals with various forms of cancer. We conducted a meta-analysis of the available literature to evaluate the association between SNHG14 and clinicopathological characteristics and patient prognosis Methods The databases PubMed/Medline, Web of Science, Cochrane Library, and Embase were combed for relevant papers published till November 2021. The odds ratio (OR) and 95% confidence interval (CI) were used to analyze dichotomous variables, while the hazard ratio (HR) and 95% CI were employed as a summary statistic for survival outcomes. In addition, the Cancer Genome Atlas TCGA (TCGA) and gene expression omnibus (GEO) database were utilized to investigate SNHG14 differential expression in pan-cancers. Cox regression and Kaplan-Meier analysis were used to investigate the prognostic significance of SNHG14 in pan-cancer. The association between the degree of SNHG14 expression in pan-cancer and immune infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI) was measured using Spearman correlations. Results A total of 21 studies with 1,080 patients, mainly from China, were included. Our results showed that elevated SNHG14 expression was significantly associated with poor overall survival (OS) (HR = 1.39; 95% CI: 1.06-1.83; P = 0.017). In addition, increased SNHG14 expression was associated with tumor size (OR = 1.60; 95% CI: 1.20-2.14; P = 0.001), TNM staging (OR = 0.54; 95% CI: 0.40-0.71; P <0.001), lymph node metastasis (OR = 1.86; 95% CI: 1.35-2.55; P <0.001), differentiation grade (OR = 1.95; 95% CI: 1.36-2.80; P <0.001), and distant metastasis (OR = 2.44; 95% CI: 1.30 -4.58; P= 0.005). However, there was no significant difference in age (OR = 1.02; 95% CI: 0.77-1.33; P = 0.863) and gender (OR = 0.98; 95% CI: 0.72-1.35; P = 0.915). Conclusion This study revealed that overexpression of SNGH14 is associated with low OS rate and clinicopathological characteristics. SNGH14 can be considered as a new tumor marker that aids in early tumor diagnosis, thus improving the prognosis of patients.

scholarly journals The prognostic significance of preoperative serum albumin in urothelial carcinoma: a systematic review and meta-analysis

2018 ◽  
Vol 38 (4) ◽  
Author(s):  
Jing Liu ◽  
Fang Wang ◽  
Shaohong Li ◽  
Wenhui Huang ◽  
Yanjuan Jia ◽  
...  
Keyword(s):  
Serum Albumin ◽  
Urothelial Carcinoma ◽  
Serum Albumin Level ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Albumin Level ◽  
Cochrane Library ◽  
Tumor Type ◽  
Poor Overall Survival ◽  
Preoperative Serum

Preoperative serum albumin has been considered to be closely correlated with the prognosis of various cancers, including urothelial carcinoma (UC). However, to date, this conclusion remains controversial. The aim of this meta-analysis is to investigate the prognostic significance of preoperative serum albumin in UC. A literature search was performed in PubMed, Web of Science, Embase, and Cochrane Library up to 4 July 2017. Herein, a total of 15506 patients from 23 studies were enrolled in our meta-analysis. Decreased preoperative serum albumin level predicted poor overall survival (OS) (HR = 1.88, 95% CI: 1.44–2.45, P<0.0001), cancer-specific survival (CSS) (HR = 2.03, 95% CI: 1.42–2.90, P=0.0001), recurrence-free survival (HR = 1.85, 95% CI: 1.15–2.97, P=0.01), 30-day complications (30dCs) after surgery (odds ratio (OR) = 1.93, 95% CI: 1.16–3.20, P=0.01), and 90-day mortality after surgery (OR = 4.24, 95% CI: 2.20–8.16, P<0.001). The subgroup analyses indicated that low preoperative serum albumin level is still positively associated with a worse prognosis of UC based on ethnicity, cut-off value, tumor type, analyses type, and sample size. Our meta-analysis indicated that reduced preoperative serum albumin level was a predictor of poor prognosis of UC.

scholarly journals Prognostic Significance of High Survivin Expression in Patients with Gastrointestinal Cancer: A Meta-Analysis

2017 ◽  
Author(s):  
Pingping Xu ◽  
Jiajia Lin ◽  
Qi Lin ◽  
Dexiang Zhu ◽  
Wentao Tang ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Survivin Expression ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Prognostic Impact ◽  
Gi Cancer ◽  
Literature Searches ◽  
The Cochrane Library

Previous studies on the prognostic impact of survivin expression in gastrointestinal (GI) cancer have yielded inconsistent results. This study was initiated to assess the relationship between survivin expression and overall survival (OS) or disease free survival (DFS) in GI cancer patients. We applied system literature searches on EMBASE, PubMed, Web of science, and the Cochrane library to conduct this up-to-date meta-analysis. Thirty studies with totally 3622 GI cancer patients were collected. The prevalence of high survivin expression in GI cancer was 0.57 (95% CI: 0.51-0.63). High survivin expression was significantly associated with shorter OS (HR 1.57, 95% CI: 1.42-1.74) and DFS (HR 1.38, 95% CI: 1.21-1.58). Subgroup analysis also showed significant association between high survivin expression and poorer OS or DFS in gastric cancer or colorectal cancer. In summary, our study indicated that high survivin expression was related to poor prognosis in GI cancer. Well-designed studies with large sample and more convincing data are needed to confirm our conclusion.

Clinicopathological and Prognostic Significance of Platelet-Lymphocyte Ratio (PLR) in Gastric Cancer: A Meta-Analysis

2019 ◽  
Author(s):  
Xunlei Zhang ◽  
Wenjing Zhao ◽  
Yang Yu ◽  
Xue Qi ◽  
Li Song ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Clinicopathological Parameters ◽  
Poor Overall Survival ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio ◽  
Inflammatory Parameters

Abstract Background: Systemic inflammatory parameters, such as the elevator PLR (platelet-lymphocyte ratio), have been found to be associated with the prognosis in gastric cancer (GC); however, the results remain controversial. So we aimed to evaluate the prognostic role of the PLR in gastric cancer by conducting this meta-analysis. Methods: We performed a systematic literature search in PubMed, Embase and the Cochrane Library. The hazard ratio (HR) /Odds Ratio (OR) and its 95% confidence (CI) of survival outcomes and clinicopathological parameters were calculated. Results: A total of 38 studies (39 cohorts) with 23,317 GC patients were included in the final meta-analysis. The pooled results showed that elevated PLR was significantly associated with poor overall survival (OS) (HR: 1.37, 95% CI: 1.25-1.51, p < 0.001; I2= 82.10%, Ph < 0.001) and disease-free survival (DFS) (HR 1.52, 95%CI 1.22–1.90, P< 0.001, I2= 88.6%, Ph< 0.001) of GC patients. Furthermore, patients with elevated PLR had a higher risk of lymph node metastasis (OR = 1.33, 95% CI: 1.03–1.70, p=0.027), serosal invasion (T3 +T4) (OR = 1.58, 95% CI: 1.09–1.31, p=0.017) and increased advanced stage (III+IV) (OR = 1.37, 95% CI: 1.00–1.89, p=0.050). Conclusions: This meta-analysis demonstrated that elevated PLR was a prognostic factor for poor OS and DFS, and associated with clinicopathological parameters in patients with GC.

Time for return to sport following total hip arthroplasty: a meta-analysis

2021 ◽  
pp. 112070002110419
Author(s):  
Ahmed A Magan ◽  
Ganan T Radhakrishnan ◽  
Babar Kayani ◽  
Flaminia Ronca ◽  
Vikas Khanduja ◽  
...  
Keyword(s):  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
English Language ◽  
Meta Analysis ◽  
Return To Sport ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
Total Hip ◽  
Patient Demographics ◽  
The Cochrane Library

Introduction: Total Hip Arthroplasty (THA) is being increasingly undertaken in younger and more active patients, with many of these patients wanting to return to sport (RTS) after surgery. However, the percentage of patients RTS and time at which they are able to get back to sport following surgery remains unknown. The objective of this meta-analysis was to determine the time patients RTS after THA. Methods: A search was performed on PUBMED, MEDLINE, EMBASE, and the Cochrane Library for trials on THA and RTS, in the English language, published from the inception of the database to October 2020. All clinical trials reporting on to RTS following THA were included. Data relating to patient demographics, methodological quality, RTS, clinical outcomes and complications were recorded. The PRISMA guidelines were used to undertake this study. Results: The initial literature search identified 1720 studies. Of these, 11 studies with 2297 patients matched the inclusion criteria. 3 studies with 154 patients demonstrated an overall pooled proportion of 40.0% (95% CI, 32.5–47.9%) of patients RTS between 2 and 3 months after surgery. 4 studies with 242 patients demonstrated an overall pooled proportion of 76.9% (95% CI, 71.5–82.0) of patients RTS by 6 months after surgery. Pooled proportion analysis from 7 trials with 560 patients demonstrated 93.9% (95% CI, 82.7–99.5%) of patients RTS between 6 and 12 months after surgery. Conclusions: Pooled proportion analysis showed increasingly more patients were able to RTS after THA over the first 1 year after surgery. There remains marked inter and intra-study variations in time for RTS but the pooled analysis shows that over 90% of patients were able to RTS at 6–12 months after THA. These finding will enable more informed discussions between patients and healthcare professionals about time for RTS following THA.

Sign in / Sign up

Export Citation Format

Share Document